Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Digital Health, Diagnostic Focus Included In FDA Commissioner's 2018 Strategy

Executive Summary

Starting out 2018, Scott Gottlieb issued a new directive to US FDA staff outlining his priorities and vision. Among the directives is to promote digital health and diagnostics by creating efficient pathways for new products in the areas and focusing on technology to help consumers better track their health.


Related Content

Top FDA Officials Warn About Non-Vetted Pharmacogenetic Tests After Latest 23andMe Approval
US FDA Greenlights First Direct-To-Consumer Cancer-Risk Test
FDA's US-First Strategy: Device Center Sets Three-Year Goals
Medtech's Unfinished Business For Congress In 2018: What's Ahead
2018 An Inflection Point For mHealth After An Active Year
A New York Minute: US FDA Leverages State's Health Department To Expedite NGS Reviews
US FDA Implements 'Firm-Based' Regulatory Approach To DTC Genetic Health Risk Tests
'Excellence' In Health-Software Design: US FDA Taps Nine Firms To Figure Out What That Means
US FDA's New Game Plan For Digital Health





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts